A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is a first‐in‐human trial of this live biotherapeutic product. The primary objective is to assess safety and tolerability in allergic subjects who are otherwise healthy, with twice daily dosing in descending age groups.
Epistemonikos ID: b1464a46d7115e0d4f84b61be78aa7ff65c86fc9
First added on: May 21, 2024